Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXNX NYSE:GKOS NASDAQ:NUVA NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXNXAxonics$70.98$70.61$67.73▼$71.05$3.63B0.82436,507 shsN/AGKOSGlaukos$97.76-1.3%$98.28$77.10▼$163.71$5.58B0.82748,406 shs599,069 shsNUVANuVasive$39.75$39.64$35.17▼$49.53$2.08B1.071.16 million shsN/ATNDMTandem Diabetes Care$14.77-3.8%$19.61$14.66▼$47.60$983.79M1.481.51 million shs1.68 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXNXAxonics0.00%0.00%0.00%0.00%+4.38%GKOSGlaukos0.00%-5.71%-4.45%+8.44%-21.25%NUVANuVasive0.00%0.00%0.00%0.00%0.00%TNDMTandem Diabetes Care0.00%-5.26%-27.63%-12.40%-67.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXNXAxonicsN/AN/AN/AN/AN/AN/AN/AN/AGKOSGlaukos4.4496 of 5 stars4.41.00.04.43.31.70.6NUVANuVasiveN/AN/AN/AN/AN/AN/AN/AN/ATNDMTandem Diabetes Care4.3154 of 5 stars4.21.00.04.94.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXNXAxonics 2.00HoldN/AN/AGKOSGlaukos 2.75Moderate Buy$134.6737.75% UpsideNUVANuVasive 0.00N/AN/AN/ATNDMTandem Diabetes Care 2.33Hold$32.71121.49% UpsideCurrent Analyst Ratings BreakdownLatest AXNX, TNDM, NUVA, and GKOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025GKOSGlaukosBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/9/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$24.00 ➝ $14.006/16/2025TNDMTandem Diabetes CareTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$24.005/22/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.005/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/2/2025GKOSGlaukosStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.005/1/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $135.005/1/2025GKOSGlaukosStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $115.005/1/2025GKOSGlaukosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$176.00 ➝ $115.005/1/2025GKOSGlaukosWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$160.00 ➝ $86.005/1/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $59.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXNXAxonics$366.38M9.90$0.13 per share561.96$12.59 per share5.64GKOSGlaukos$383.48M14.57N/AN/A$13.91 per share7.03NUVANuVasive$1.23B1.70$4.96 per share8.01$17.02 per share2.34TNDMTandem Diabetes Care$940.20M1.05N/AN/A$4.01 per share3.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXNXAxonics-$6.09M-$0.12N/A80.66N/A-1.31%0.36%0.31%N/AGKOSGlaukos-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)NUVANuVasive$40.41M$0.5079.5015.35N/A2.32%12.17%4.88%N/ATNDMTandem Diabetes Care-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%8/6/2025 (Confirmed)Latest AXNX, TNDM, NUVA, and GKOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40N/AN/AN/A$238.39 millionN/A7/30/2025Q2 2025GKOSGlaukos-$0.26N/AN/AN/A$115.49 millionN/A4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million4/30/2025Q1 2025TNDMTandem Diabetes Care-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXNXAxonicsN/AN/AN/AN/AN/AGKOSGlaukosN/AN/AN/AN/AN/ANUVANuVasiveN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXNXAxonicsN/A8.166.40GKOSGlaukos0.096.495.62NUVANuVasive0.501.250.65TNDMTandem Diabetes Care1.992.301.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXNXAxonics99.48%GKOSGlaukos99.04%NUVANuVasiveN/ATNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipAXNXAxonics1.85%GKOSGlaukos5.80%NUVANuVasive0.53%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXNXAxonics61051.11 million50.16 millionOptionableGKOSGlaukos78057.14 million53.83 millionOptionableNUVANuVasive3,00052.45 million52.17 millionOptionableTNDMTandem Diabetes Care2,65066.61 million65.34 millionOptionableAXNX, TNDM, NUVA, and GKOS HeadlinesRecent News About These CompaniesTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by AnalystsJuly 20 at 2:54 AM | marketbeat.comHussman Strategic Advisors Inc. Makes New $1.21 Million Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 19 at 8:00 AM | marketbeat.comFY2025 Earnings Estimate for TNDM Issued By Leerink PartnrsJuly 18 at 3:01 AM | americanbankingnews.comTandem Diabetes Care's SWOT analysis: stock faces headwinds amid market shiftsJuly 17 at 10:55 PM | investing.comWhat is Leerink Partnrs' Estimate for TNDM FY2025 Earnings?July 16, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Hits New 52-Week Low - Here's What HappenedJuly 15, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Stephens Investment Management Group LLCJuly 13, 2025 | marketbeat.comEarnings Forecast & History for Tandem Diabetes Care Inc (TNDM) | Price ...July 12, 2025 | investing.comCitigroup Reaffirms Sell Rating for Tandem Diabetes Care (NASDAQ:TNDM)July 11, 2025 | americanbankingnews.comTandem Diabetes stock falls after Citi downgrades to Sell on competition concernsJuly 9, 2025 | au.investing.comCiti adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem DiabetesJuly 9, 2025 | finance.yahoo.comTandem Diabetes Shares Drop Following Citi Downgrade Over Rising CompetitionJuly 9, 2025 | msn.comWhy Tandem Diabetes (TNDM) Shares Are Sliding TodayJuly 9, 2025 | msn.comTandem Diabetes Care (NASDAQ:TNDM) Sets New 12-Month Low - Here's WhyJuly 9, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Given "Sell" Rating at CitigroupJuly 9, 2025 | marketbeat.comFurther weakness as Tandem Diabetes Care (NASDAQ:TNDM) drops 10.0% this week, taking five-year losses to 83%July 7, 2025 | finance.yahoo.comMirae Asset Global Investments Co. Ltd. Sells 265,554 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)July 6, 2025 | marketbeat.comTandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 - MorningstarJuly 2, 2025 | morningstar.comMRSI Alert: Tandem Diabetes Care (TNDM) Now OversoldJuly 2, 2025 | nasdaq.comTNDM - Tandem Diabetes Care Inc Key Metrics - MorningstarJuly 1, 2025 | morningstar.comMTandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025July 1, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXNX, TNDM, NUVA, and GKOS Company DescriptionsAxonics NASDAQ:AXNXAxonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Glaukos NYSE:GKOS$97.76 -1.24 (-1.25%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$97.72 -0.04 (-0.04%) As of 07/18/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.NuVasive NASDAQ:NUVANuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.Tandem Diabetes Care NASDAQ:TNDM$14.77 -0.59 (-3.84%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$14.78 +0.01 (+0.07%) As of 07/18/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
